Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
about
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerSigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinomaConjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancerMultifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: synthesis, characterization, target-specificity, and renal clearance.Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered releaseThe σ2 receptor: a novel protein for the imaging and treatment of cancer.Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies.Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery.Early development of sigma-receptor ligands.Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site.Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy.Characterization of spherulites as a lipidic carrier for low and high molecular weight agentsPathways driving the endocytosis of mutant and wild-type EGFR in cancer.Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1.The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.Fluorescent derivatives of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells.Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes.Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signalingSigma-2 ligands induce tumour cell death by multiple signalling pathways.Characterization of pulmonary sigma receptors by radioligand bindingLysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.Sigma receptors [σRs]: biology in normal and diseased statesAntitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluationNew N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents.Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.Synthesis and biological characterisation of 18F-SIG343 and 18F-SIG353, novel and high selectivity σ2 radiotracers, for tumour imaging properties.Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy.Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.Non-invasive molecular imaging for preclinical cancer therapeutic development.The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET).Tactics for preclinical validation of receptor-binding radiotracers.Functional assays to define agonists and antagonists of the sigma-2 receptor.Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016).Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.2-Aminopyridine derivatives as potential σ(2) receptor antagonists.Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers
P2860
Q28468300-3BA0156C-FF94-4A6E-986D-7F6E4F105E6FQ30487033-949FE244-9648-40B3-BAE6-EF33C7FAB734Q33589984-D74E815C-BF0D-48F7-AD89-DCD8295F1DFDQ33693048-B3DCFEE5-1D10-459C-8AFB-BE96516E0D0DQ33693052-1A82DE50-75B9-4071-863F-250BA7DCAFE7Q33782364-9DA64D20-4C11-4777-B3FC-BE8012B68D41Q33849311-D606C0C2-DF37-4EDF-ACED-579D509E894DQ34052669-58869B3F-506C-4613-AB56-9236C96025D9Q34146404-05C98FDD-4A33-4CF9-A400-5FEA8C5D8076Q34172682-5A1FBD7F-935D-451D-8FCF-7CABDACC17BCQ34197697-64D2E32D-669D-45BE-9AD9-4B4D91E29D07Q34362333-A27E7E27-7E01-46CF-AC18-4D7E84B9A58DQ34665722-2B2FAEDC-10A2-446A-8222-549C23B8434BQ34781357-553AAAFE-233D-4B71-8FCB-4F54E72824B7Q35000636-B800DC64-AF1D-4AFC-816B-18EA27FC664EQ35021013-A52A40C7-70A1-4EF6-B316-556D233F5A31Q35234944-C7183C90-C2D2-44F4-B513-CBE2D46E186AQ35591598-3B5F1843-2877-470F-BCC9-9738BE220905Q35652832-46283A45-B34F-4BE3-8C57-CDB22B089208Q35879869-FA44B425-0C39-4759-9E7C-14433F14C486Q35977409-8CDFB4C7-847B-4F72-86C7-FB347C286B64Q36150331-57DFA700-6AE9-44AA-B858-4CA88489CC88Q36249357-DBFFC5C0-B765-47FE-91A2-311D9A62C05CQ36551212-13DC1EF3-5462-484C-91AA-94CB8647CA1FQ37000551-1A59D3AF-C02A-49AC-A40A-47E296F099A5Q37065888-70986B1E-262B-4B74-B051-A7D3B3FFAAD3Q37150075-ADC4F2DA-7909-4C85-A647-D38519E65D47Q37161130-1CE17F06-4217-4FAF-B332-64F558904902Q37376094-E00BA594-D411-44CE-9458-B7487EFCD5CEQ37427252-BA521A21-BB2E-4A4C-9FC4-FC8F7C3D452FQ37777989-09BA4207-3305-4484-883F-C4E869A421BCQ38024011-AE8AEC1E-EA54-47EF-9863-BFB20D675313Q38089102-ABA1FDFF-362B-40CC-B863-4E83CC3316D2Q38166977-AC704DF8-9783-4DF6-B819-E0D514F6735AQ38984519-49D3F7CC-3CDF-4652-9142-10EF2EB9EDC4Q39044023-7B9A5B7C-2B41-4917-8922-0124A89289CBQ39067013-B06369AF-B42B-4479-A722-D8C2C90362A3Q39289664-40904A41-5626-4691-B02F-830062018E92Q39297889-D2D18114-0BB2-4544-9D65-4F95396BF91FQ39377369-EEDC9B6E-CC06-4E9F-8031-3173311F7770
P2860
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.
@ast
Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.
@en
type
label
Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.
@ast
Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.
@en
prefLabel
Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.
@ast
Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.
@en
P2093
P2860
P356
P1433
P1476
Selective sigma-2 ligands pref ...... iagnostic imaging and therapy.
@en
P2093
Fabian Johnston
Hiroyuki Kashiwagi
Jonathan E McDunn
Katherine Chang
Kathryn Trinkaus
Lynne Jones
Peter O Simon
Peter S Goedegebuure
Robert H Mach
P2860
P2888
P356
10.1186/1476-4598-6-48
P577
2007-07-15T00:00:00Z
P5875
P6179
1030019276